CCK Receptor Antagonists

General Pharmacology

Volumn 31, Issue 4, 1998, Pages 519-524

  Dunlop, John ^a  

^a PFIZER INC   (United States)

Author keywords

Benzodiazepine antagonist; CCK A receptor; CCK B receptor; Cholecystokinin (CCK); L 365,260; L 740,093; YM022

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 1 (2' METHYLPHENACYL) 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 1 [5 (3 AZABICYCLO[3.2.2]NON 3 YL) 2,3 DIHYDRO 1 METHYL 2 OXO 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEVAZEPIDE; RECEPTOR SUBTYPE;

BINDING SITE; BRAIN REGION; CHO CELL; DRUG ACTIVITY; DRUG RECEPTOR BINDING; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BENZODIAZEPINES; BENZODIAZEPINONES; CELLS, CULTURED; HUMANS; PHENYLUREA COMPOUNDS; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ;

EID: 0032189179     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00078-0     Document Type: Review

References (51)

1. Abelson J.L. Cholecystokinin in psychiatric research. a time for cautious excitement J. Psychiatric Res. 29:1995;389-396.
2. Adams J.B., Pyke R.E., Costa J., Cutler N.R., Schweizer E., Wilcox C.S., Wisselink P.G., Greiner M., Pierce M.W., Pande A.C. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J. Clin. Psychopharm. 15:1995;428-434.
3. Akiyama T., Tachibana I., Hirohata Y., Shirohara H., Yamamoto Y., Otsuki M. Pharmacological profile of TP-680, a new cholecystokinin-A receptor antagonist. Br. J. Pharmac. 117:1996;1558-1564.
4. Ballaz S., Barber A., Fortuno A., Del Rio J., Martin-Martinez M., Gomez-Monterrey I., Herranz R., Gonzalez-Muniz R., Garcia-Lopez M.-T. Pharmacological evaluation of IQM-95,333, a highly selective CCK-A receptor antagonist with anxiolytic activity in animal models. Br. J. Pharmac. 121:1997;759-767.
5. Bradwejn J., Koszycki D., Meterissian G. Cholecystokinin-tetrapeptide induces panic attack in patients with panic disorder. Can. J. Psychiatry. 35:1990;83-85.
6. Bradwejn J., Koszycki D., Couetoux du Terre A., van Megan H., den Boer J., Westenberg H. The panicogenic effects of cholecystokinin-tetrapeptide are antagonised by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch. Gen. Psychiatry. 51:1994;486-493.
7. Bradwejn J., Koszycki D., Paradis M., Reece P., Hinton J., Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biological Psychiatry. 38:1995;742-746.
8. Chang R.S., Lotti V.J., Monaghan R.L., Birnbaum J., Stapley E.O., Goetz M.A., Albers-Schonberg G., Patchett A.A., Liesch J.M., Hensens O.D., Springer J.P. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science. 230:1985;177-179.
9. Chang R.S.L., Lotti V.J. Biochemical and pharmacological characterization of an extremely potent and selective non-peptide cholecystokinin antagonist. Proc. Natl. Acad. Sci. USA. 83:1986;4923-4926.
10. Charrier D., Dangoumau L., Puech A.J., Hamon M., Thiebot M.-H. Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats. Psychopharmacology. 121:1995;127-134.
11. Dawson G.R., Rupniak N.M.J., Iverson S.D., Curnow R., Tye S., Stanhope K.J., Tricklebank M.D. Lack of effect of CCK-B receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Psychopharmacology. 121:1995;109-117.
12. De Weerth A., Pisegna J.R., Huppi K., Wank S.A. Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor. Biochem. Biophys. Res. Commun. 194:1993;811-818.
13. Deschenes R.J., Lorenz L.J., Haun R.S., Roos B.A., Collier K.J., Dixon J.E. Cloning and sequence analysis of a cDNA encoding rat preprocholecystokinin. Proc. Natl. Acad. Sci. USA. 81:1984;726-730.
14. Dunlop J., Brammer N., Ennis C. Pharmacological characterisation of a Chinese hamster ovary cell line transfected with the human CCK-B receptor gene. Neuropeptides. 30:1996;359-363.
15. Dunlop J., Zhang Y., Evans N. Full and partial agonist activity of C-terminal cholecystokinin peptides at the cloned human CCK-A receptor expressed in Chinese hamster ovary cells. Peptides. 18:1997;865-868. a.
16. Dunlop J., Brammer N., Evans N., Ennis C. YM022 ((R)-1-[2,3-dihydro-1- (2′-methylphenacyl) -2-oxo-5-phenyl-1H-1, 4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea). an irreversible cholecystokinin type-B receptor antagonist Biochem. Pharmac. 54:1997;81-85. b.
17. Dunlop J., Pass I., Ennis C. The cholecystokinin-B receptor antagonist L-740,093 produces an insurmountable antagonism of CCK-4 stimulated functional response in cells expressing the human CCK-B receptor. Neuropeptides. 32:1998;157-160.
18. Gardner J.D., Jensen R.T. Cholecystokinin receptor antagonists. Am. J. Physiol. 246:1984;G471-G476.
19. Hill D.R., Campbell N.J., Shaw T.M., Woodruff G.N. Autoradiographic localisation and biochemical characterisation of peripheral type CCK receptors in rat CNS using highly selective non-peptide CCK antagonists. J. Neurosci. 7:1987;2967-2976.
20. Horwell D.C. Development of CCK-B antagonists. Neuropeptides. 19(suppl):1991;57-64.
21. Howbert J.J., Lobb K.L., Brown R.F., Reel J.K., Neel D.A., Mason N.R., Mendelsohn L.G. A novel series of non-peptide CCK and gastrin antagonists. medicinal chemistry and electrophysiological demonstration of antagonism Dourish C.T., Cooper S.J., Iverson S.D., Iverson L.L. Multiple Cholecystokinin Receptors - Progress Towards CNS Therapeutics. 1992;28-37 Oxford University Press, London.
22. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D.C., Hunter J.C., Pinnock R.D., Woodruff G.N. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA. 87:1990;6728-6732.
23. Innis R.B., Snyder S.H. Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. USA. 77:1980;6917-6922.
24. Jensen R.T., Wank S.A., Rowley W.H., Sato S., Gardner J.D. Interactions of cholecystokinin with pancreatic acinar cells. a well studied model of peripheral action of CCK Trends Pharmacol. Sci. 10:1989;418-423.
25. Kopin A.S., Lee Y.M., McBride E.W., Miller L.J., Lu M., Lin H.Y., Kolakowski L.F. Jr., Beinborn M. Expression cloning and characterisation of the canine parietal cell gastrin receptor. Proc. Natl. Acad. Sci. USA. 89:1992;3605-3609.
26. Kramer M.S., Cutler N.R., Ballenger J.C., Patterson W.M., Mendels J., Chenault A., Shrivastava R., Matzura-Wolfe D., Lines C., Reines S. A placebo controlled trial of L-365,260, a CCK-B receptor antagonist, in panic disorder. Biol. Psychiatry. 37:1995;462-466.
27. 2+-mobilisation in a pituitary cell line. Eur. J. Pharmac. 221:1992;99-105.
28. Lee Y.-M., Beinborn M., McBride E.W., Lu M., Kolakowski L.F., Kopin A.S. The human brain cholecystokinin-B/gastrin receptor. J. Biol. Chem. 268:1993;8164-8169.
29. 2+ concentration in the human JURKAT T lymphocyte cell line. Eur. J. Pharmac. 245:1993;241-246.
30. Lotti V.J., Chang R.S.L. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor ligand L-365,260. Eur. J. Pharmac. 162:1989;273-280.
31. Makovec F., Peris W., Revel L., Giovanetti R., Mennuni L., Rovati L.C. Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives. J. Med. Chem. 35:1992;28-38.
32. Martin-Martinez M., Bartolome-Nebreda J.M., Gomez-Monterrey I., Gonzalez-Muniz R., Garcia-Lopez M.-T., Ballaz S., Barber A., Fortuno A., Del Rio J., Herranz R. Synthesis and stereochemical structure-activity relationships of 1,3-dioxo-perhydropyrido[1,2-c] pyrimidine derivatives. potent and selective cholecystokinin-A receptors antagonists J. Med. Chem. 40:1997;3402-3407.
33. Matozaki T., Sakamoto C., Nagao M., Nishizaki H., Baba S. G protein in stimulation of PI hydrolysis by CCK in isolated rat pancreatic acinar cells. Am. J. Physiol. 255:1988;E652-E659.
34. 2+ mobilisation and phospholipid hydrolysis in isolated rat pancreatic acini. Studies using a new cholecystokinin analog, JMV-180. J. Biol. Chem. 265:1990;6247-6254.
35. Moran T.H., Schwartz G.J. Neurobiology of cholecystokinin. Crit. Rev. Neurobiol. 9:1994;1-28.
36. Mutt V., Jorpes J.E. Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with thrombin and with trypsin. Eur. J. Biochem. 6:1968;156-162.
37. Nishida A., Miyata K., Tsutsumi R., Yuki H., Akuzawa S., Kobayashi A., Kamato T., Ito H., Yamano M., Katuyama Y., Satoh M., Ohta M., Honda K. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2′-methylphenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J. Pharm. Exp. Ther. 269:1994;725-731.
38. Ohtsuka T., Kudoh T., Shimma N., Kotaki H., Nakayama N., Itezono Y., Fujisaki N., Watanabe J., Yokose K., Seto H. Tetronothiodin, a novel cholecystokinin type-B receptor antagonist produced by Streptomyces sp. Journal of Antibiotics. 45:1992;140-143.
39. Patel S., Smith A.J., Chapman K.L., Fletcher A.E., Kemp J.A., Marshall G.R., Hargreaves R.J., Ryecraft W., Iverson L.L., Iverson S.D., Baker R., Showell G.A., Bourrain S., Neduvelil J.G., Matassa V.G., Freedman S.B. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. Mol. Pharmac. 46:1994;943-948.
40. Pendley C.E., Fitzpatrick L.R., Capolino A.J., Davis M.A., Esterline N.J., Jakubowska A., Bertrand P., Guyon C., Dubroeucq M.C., Martin G.E. RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat. J. Pharmacol. Exp. Ther. 273:1995;1015-1022.
41. Ratuad S., Darche F., Piot O., Stutzmann J.M., Bohme G.A., Blanchard J.C. "Anxiolytic" effect of CCK-antagonists on plus-maze behaviour in mice. Brain Res. 548:1991;315-317.
42. Revel L., Ferrari F., Makovec F., Rovati L.C., Impicciatore M. Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative. Eur. J. Pharmac. 216:1992;217-224.
43. 2+-mobilisation Eur. J. Pharmac. 269:1994;249-254.
44. Singh L., Lewis A.S., Field M.J., Hughes J., Woodruff G.N. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc. Natl. Acad. Sci. USA. 88:1991;1130-1133.
45. Takinama Y., Yuki H., Nishida A., Akuzawa S., Uchida A., Takemoto Y., Ohta M., Satoh M., Semple G., Miyata K. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Alim. Pharm. Ther. 11:1997;113-120.
46. Van Megan H.J.G.M., Westenberg H.G.M., Den Boer J.A., Slaap B., Van Es-Radhakishun F., Pande A.C. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology. 129:1997;243-248.
47. Wank S.A., Harkins R., Jensen R.T., Shapira H., de Weerth A., Slattery T. Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc. Natl. Acad. Sci. USA. 89:1992;3125-3129. a.
48. Wank S.A., Pisegna J.R., de Weerth A. Brain and gastrointestinal cholecystokinin receptor family. structure and functional expression Proc. Natl. Acad Sci. USA. 89:1992;8691-8695. b.
49. Williams J.A. Cholecystokinin. a hormone and neurotransmitter Biomed. Res. 3:1982;107-115.
50. Witte D.G., Nadzan A.M., Martinez J., Rodriguez M., Lin C.W. Characterisation of the novel CCK analogs JMV-180, JMV-320 and JMV-332 in H345 cells. Peptides. 13:1992;1227-1232.
51. Woodruff G.N., Hill D.R., Boden P., Pinnock R., Singh L., Hughes J. Functional role of brain CCK receptors. Neuropeptides. 19(suppl):1991;45-56.